• Provide medical expertise and scientific leadership across Natera’s oncology portfolio • Lead the clinical strategy and evidence generation for melanoma, non-melanoma skin cancers, and pan-tumor immunotherapy indications • Partner closely with clinical development, medical affairs, and commercial teams to translate emerging evidence into meaningful clinical practice applications • Collaborate with key opinion leaders (KOLs), cooperative groups, and academic investigators to validate and expand clinical use cases for ctDNA-based diagnostics in immuno-oncology • Provide field-facing education and strategic guidance to healthcare providers, payers, and advocacy organizations on clinical utility, interpretation, and impact of MRD and response monitoring in immune-treated populations • Identify and address barriers to adoption by aligning evidence generation, messaging, and stakeholder engagement with evolving standards of care and health system needs • Serve as the medical and scientific spokesperson for skin and immuno-oncology programs, • Collaborate on clinical trial design, data analysis, and publication strategy related to ctDNA applications in melanoma and other immune-responsive solid tumors